CSIMarket
 
Omniab Inc   (NASDAQ: OABI)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $3.6400 $0.07 1.961%
Day's High: $3.65 Week Perf: 1.11 %
Day's Low: $ 3.54 30 Day Perf: 14.11 %
Volume (M): 279 52 Wk High: $ 6.55
Volume (M$): $ 1,015 52 Wk Avg: $4.32
Open: $3.57 52 Wk Low: $3.10



 Market Capitalization (Millions $) 373
 Shares Outstanding (Millions) 102
 Employees -
 Revenues (TTM) (Millions $) 20
 Net Income (TTM) (Millions $) -63
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 2

Omniab Inc
Omnia Inc. is a multinational technology company specializing in the development and manufacturing of innovative electronic products. The company is known for its wide range of consumer electronics, such as smartphones, tablets, wearable devices, and smart home appliances.

Omnia Inc. has established itself as a major player in the tech industry, with a strong emphasis on cutting-edge technology and design. The company prides itself on its commitment to delivering high-quality and reliable products that cater to the evolving needs and preferences of its global customer base.

In addition to its consumer electronics segment, Omnia Inc. also operates in other sectors, including telecommunications infrastructure, software development, and cloud services. The company has a diverse portfolio of offerings, which enables it to tap into various segments of the market and maintain a competitive edge.

Omnia Inc. has a global presence, with manufacturing and research facilities located in multiple countries. The company's products are sold in numerous markets worldwide, and it maintains a robust distribution network to reach customers effectively.

Overall, Omniab Inc. is a dynamic and forward-thinking technology company that continues to innovate and shape the industry with its cutting-edge products and services.


   Company Address: 5980 Horton Street, Suite 600 Emeryville 94608 CA
   Company Phone Number: 250-7800   Stock Exchange / Ticker: NASDAQ OABI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRL   -4.89%    
MXCT   -7.29%    
ABCL        1.29% 
BLUE        15.26% 
BRKR   -7.99%    
NTLA   -1.53%    
• View Complete Report
   



Business Update

The Potential of Genetic Engineering: Chickens Producing Heavy Chain-Only Single-Domain Antibodies

Published Tue, Jun 4 2024 12:38 AM UTC

In a significant breakthrough for the biotechnology industry, OmniAb, Inc. has recently published a peer-reviewed scientific paper in the Journal of Immunology, unv...

Business Update

Advancements in Antibody Engineering: Chickens Engineered to Produce Heavy Chain-Only Single-Domain Antibodies

Published Mon, Jun 3 2024 9:38 PM UTC

OmniAb, Inc., a biotechnology company based in Emeryville, California, has recently made significant breakthroughs in the field of antibody engineering. Through the publication of a scientific paper in the Journal of Immunology, the company has demonstrated that chickens can be genetically modified to produce functional heavy chain-only single-domain antibodies (sdAbs). This...

Business Update

OmniAb's xPloration: Marrying High-Throughput Screening with AI to Revolutionize Antibody Discovery'

Published Thu, May 16 2024 12:15 AM UTC

OmniAb Unveils Groundbreaking High-Throughput Single B-cell Screening Platform xPloration at the 20th Annual PEGS Boston Summit EMERYVILLE, Calif. - OmniAb, Inc. (Nasdaq: OABI), a pioneer in the biopharmaceutical industry, captivated attendees at the 20th Annual PEGS Boston - The Essential Protein & Antibody Engineering Summit, with a presentation of its sophisticated high-t...

Business Update

OmniAb's xPloration Platform: Unleashing the Power of AI in Antibody Engineering

Published Wed, May 15 2024 10:15 PM UTC

OmniAb Revolutionizes Antibody Engineering with Innovative xPloration PlatformEmeryville, Calif. - OmniAb, Inc. made a significant impact at the 20th Annual PEGS Boston Summit by unveiling its groundbreaking high-throughput single B-cell screening platform called xPloration. This innovative technology, which incorporates machine learning and Artificial Intelligence (AI), has...

Omniab Inc

Omniab Inc Faces Uphill Battle After Disastrous Fiscal Quarter

Investors in Omniab Inc (NASDAQ: OABI) may be feeling anxious after the company recently declared a disastrous fiscal quarter ending March 31, 2024. The company reported a staggering 77.534% decrease in revenue, falling to $3.80 million. Additionally, the shortfall per share has increased to $-0.19 from the previous year.
Comparatively, the rest of the Medical Laboratories industry saw a revenue improvement in the first quarter of 2024. However, Omniab Inc's performance stands in stark contrast, with a sequential revenue decrease of 21.174% from the previous quarter.







Omniab Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com